PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or palliative chemotherapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Pancreatic Cancer |
Biological: PANVAC™-VF |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen |
| Estimated Enrollment: | 250 |
| Study Start Date: | June 2004 |
PANVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the body can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer.
All patients will be required to sign an informed consent prior to the performance of any study-related procedures. Patients will be screened for eligibility within 14 days prior to their anticipated treatment start date (Day 0). Patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a treatment assignment. The ratio of active treatment to control is 1:1 (PANVAC-VF: best supportive care or palliative chemotherapy).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients > 18 years of age who have been vaccinated against smallpox;
- Histologically confirmed diagnosis of adenocarcinoma of the pancreas;
- Patient has metastatic (Stage IV) disease;
- ECOG performance status 0-1;
- Failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry.
Exclusion Criteria:
- Prior or concurrent immunotherapy for cancer;
- Radiation therapy within 28 days prior to registration;
- Systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration;
- Significant cardiovascular abnormalities or diseases;
- Known positive for HIV, hepatitis B and/or C;
- Evidence of immunodeficiency or immune suppression.
Contacts and Locations
Show 62 Study Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00088660 History of Changes |
| Other Study ID Numbers: | TBC-PAN-003 |
| Study First Received: | July 30, 2004 |
| Last Updated: | February 7, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Therion Biologics Corporation:
|
Metastatic |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Gemcitabine Antimetabolites, Antineoplastic Antimetabolites |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Radiation-Sensitizing Agents |
ClinicalTrials.gov processed this record on May 19, 2013